CN105232619A - Lysimachia trientaloides hemsl. extract as well as preparation method and medical application thereof - Google Patents
Lysimachia trientaloides hemsl. extract as well as preparation method and medical application thereof Download PDFInfo
- Publication number
- CN105232619A CN105232619A CN201510733252.XA CN201510733252A CN105232619A CN 105232619 A CN105232619 A CN 105232619A CN 201510733252 A CN201510733252 A CN 201510733252A CN 105232619 A CN105232619 A CN 105232619A
- Authority
- CN
- China
- Prior art keywords
- extract
- ethanol
- lysimachia trientaloides
- trientaloides hemsl
- parts
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
The invention discloses a lysimachia trientaloides hemsl. extract as well as a preparation method and medical application thereof. The preparation method of the extract comprises the following steps: (a) mixing and crushing materials, wherein every 100 parts of the medicinal materials include 80-90 parts of dried lysimachia trientaloides hemsl. and 10-20 parts of liquorice root in parts by weight, performing heat reflux extraction on the mixed and crushed materials by virtue of an ethanol solution with concentration being 60%, combining extracting solutions, and concentrating the combined extracting solutions until no alcohol smell exists so as to obtain an ethanol extracting concentrated solution; (b) diluting the ethanol extracting concentrated solution obtained in the step (a), sequentially extracting the diluted extracting solution by virtue of petroleum ether, ethyl acetate and water-saturated normal butanol, and concentrating under reduced pressure so as to respectively obtain a petroleum ether extract, an ethyl acetate extract and a normal butanol extract; and (c) dissolving the normal butanol extract by virtue of water, filtering, enriching active ingredients by virtue of macroporous resin, flushing 12 column volumes by virtue of ethanol with concentration being 8% so as to remove high-polarity ingredients and flushing 10 column volumes by virtue of ethanol with concentration being 70%, collecting an eluent of the ethanol with concentration being 70%, and concentrating under reduced pressure so as to obtain the extract. The extract has a function of resisting brain aging; and the extract can be developed as a medicine for resisting brain aging.
Description
Technical field
The present invention relates to Chinese medicine extract field, be specifically related to a kind of Lysimachia trientaloides Hemsl. extract, the preparation method of this extract and medical usage, it is old that this extract may be used for anti senile.
Background technology
Lysimachia trientaloides Hemsl. is root or the herb of the narrow leaf Herba lysimachiae capillipedis of Ofthe Primulaceae.The whole year can adopt.Have another name called infantile convulsion umbrella (" Guizhou side among the people medicine collection "), Rhizoma Arisaematis (" Kweiyang medicinal herbs among the people "), public Cortex torricelliae tiliifoliae (" Guizhou medical herbs ").
The narrow leaf Herba lysimachiae capillipedis of Lysimachia trientaloides Hemsl. original shape state is perennial herb, height about 30 centimetres.Fibrous root is faint yellow.Stem is grown thickly, not branch, and nearly base portion is red, has pubescence.Upper green, joint slightly expands, and has pubescence.The lower portion of the stem leaf is degenerated, very little, as flakey, to life; Stem top is verticillate, mostly is 4 ~ 7, differs in size, circular to obovate, long 4 ~ 14 centimetres, wide 2 ~ 10 centimetres, the anxious point of tip, and Quan Yuan, slightly becomes ripple shape, the wealthy wedge shape of base portion to narrow wedge shape, above light green, below pale green; Petiole without, or extremely short, purplish red.Flowers are born in stem top; Calyx symphysis globulate, top 5 is split, sliver wire lanceolar, light green; Corolla is yellow, 5 drastic cracks; Stamen 5, and is born in corolla pipe; Ovary is red, and style is elongated, Room 1, and ovule is most, and capsule is spherical.May at florescence.Really 5 ~ June of phase.
Summary of the invention
The object of the present invention is to provide a kind of Lysimachia trientaloides Hemsl. extract, its preparation method and liquid phase analysis method, the pharmaceutical preparation containing this extract and utilize this extract to prepare the purposes of the old medicine for the treatment of anti senile.
Above-mentioned purpose of the present invention is achieved by technical scheme below:
A kind of Lysimachia trientaloides Hemsl. extract, this extract is prepared by following methods:
A () by weight, every 100 parts of medical materials comprise dry Lysimachia trientaloides Hemsl. 80 ~ 90 parts and 10 ~ 20 parts, Radix Glycyrrhizae, co-grinding, and with 60% alcoholic solution circumfluence distillation, merge extractive liquid, is concentrated into and obtains ethanol extraction concentrated solution without alcohol taste; B (), by step (a) gained ethanol extraction concentrated solution dilute with water, is used petroleum ether, ethyl acetate and water saturated n-butanol extraction successively, concentrating under reduced pressure, is obtained petroleum ether extract, acetic acid ethyl ester extract and n-butyl alcohol extract respectively; C () n-butyl alcohol extract water dissolution, filters, uses macroporous resin enrichment active component, first remove large polar component with 8% alcohol flushing, 12 column volumes, then use 70% ethanol elution, 10 column volumes, collect 70% eluent, concentrating under reduced pressure and get final product.
Further, macroporous resin described in step (c) is AB-8 type macroporous resin.
In order to be controlled the differences between batches of extract prepared by different batches by the method setting up HPLC finger printing, the liquid phase analysis method of described extract is:
Chromatographic column: AgilentZorbaxSB-C18 post (4.6mm × 250mm, 5 μm);
Mobile phase: A is acetonitrile, and B is 0.4% phosphoric acid solution;
Gradient elution program: 0 ~ 5min, A10% → 15%; 5 ~ 15min, A15% → 50%; 15 ~ 23min, A50% → 80%; 23 ~ 25min, A80% → 10%; 25 ~ 30min, A10%
Flow rate of mobile phase: 1.0mLmin
-1;
Determined wavelength: 280nm;
Column temperature: 30 DEG C;
Sample size: 10 μ L.
Pharmaceutical preparation, the described extract containing treatment effective dose and pharmaceutically acceptable carrier.
The application of described extract in the medicine that preparation treatment anti senile is old.
The application of described pharmaceutical preparation in the medicine that preparation treatment anti senile is old.
When extract of the present invention is used as medicine, directly can uses, or use in the form of a pharmaceutical preparation.
Described pharmaceutical preparation contains the Lysimachia trientaloides Hemsl. extract of the present invention for the treatment of effective dose, and all the other are acceptable on materia medica, nontoxic to humans and animals and pharmaceutically suitable carrier of inertia and/or excipient.
Described pharmaceutically suitable carrier or excipient are that one or more are selected from solid, semisolid and liquid diluent, filler and pharmaceutical preparation adjuvant.Pharmaceutical preparation of the present invention is used with the form of per weight dose.Extract of the present invention is applied to by form that is oral or injection the patient needing treatment.For time oral, tablet, slow releasing tablet, controlled release tablet, capsule, drop pill, micropill, suspensoid, Emulsion, powder or granule, oral liquid etc. can be made into; During for injecting, can be made into aqueous or oily solution, aseptic powder injection, liposome or the Emulsion etc. of sterilizing.
Advantage of the present invention: the present invention by extracting the Lysimachia trientaloides Hemsl. of drying, remove impurity, enrichment process, the extract with the old function of anti senile can be obtained; Liquid phase analysis method provided by the invention may be used for the finger printing setting up this extract, for controlling the differences between batches of extract prepared by different batches.
Accompanying drawing explanation
Fig. 1 is Lysimachia trientaloides Hemsl. extractive HPLC chromatograms.
Detailed description of the invention
Further illustrate essentiality content of the present invention below in conjunction with embodiment, but do not limit scope with this.Although be explained in detail the present invention with reference to preferred embodiment, those of ordinary skill in the art should be appreciated that and can modify to technical scheme of the present invention or equivalent replacement, and does not depart from essence and the scope of technical solution of the present invention.
Embodiment 1: extract preparation (Lysimachia trientaloides Hemsl. 85 parts, 15 parts, Radix Glycyrrhizae)
Crude drug source: Lysimachia trientaloides Hemsl. and Radix Glycyrrhizae dry rhizome are purchased from Hui nationality's Chinese Medicinal Materials Markets.
Main agents: food-grade ethanol is purchased from Shanghai Ling Feng chemical reagent company limited; Pharmaceutical grade AB-8 macroporous resin is purchased from sky tunami letter resin company limited; Acetonitrile is HPLC level, is purchased from TEDIA; 85% phosphoric acid is HPLC level, is purchased from TEDIA; Chromatographic grade pure water is heartily pure water.
Preparation method: by the Radix Glycyrrhizae dry rhizome co-grinding of the Lysimachia trientaloides Hemsl. of 8.5kg drying and 1.5kg, with 60% alcoholic solution circumfluence distillation (25L × 3 time), merge extractive liquid, is concentrated into and obtains ethanol extraction concentrated solution (2L) without alcohol taste; Gained ethanol extraction concentrated solution is diluted with water to 3L, petroleum ether (3L × 3 time), ethyl acetate (3L × 3 time) and water saturated n-butyl alcohol (3L × 3 time) is used to extract successively, concentrating under reduced pressure, obtains petroleum ether extract, acetic acid ethyl ester extract and n-butyl alcohol extract 212g respectively; (c) n-butyl alcohol extract 1.5L water dissolution, medical absorbent cotton filters, with AB-8 macroporous resin (2kg, column volume 1.5L) deposition activity composition, first use 8% alcohol flushing, 12 column volumes (18L) to remove large polar component, then use 70% ethanol elution, 10 column volumes (15L), collect 70% eluent, concentrating under reduced pressure, obtains Lysimachia trientaloides Hemsl. extract and is about 120g.
Embodiment 2: extract preparation (Lysimachia trientaloides Hemsl. 80 parts, 20 parts, Radix Glycyrrhizae)
Preparation method: by the Radix Glycyrrhizae dry rhizome co-grinding of the Lysimachia trientaloides Hemsl. of 8kg drying and 2kg, with 60% alcoholic solution circumfluence distillation (25L × 3 time), merge extractive liquid, is concentrated into and obtains ethanol extraction concentrated solution (2L) without alcohol taste; Gained ethanol extraction concentrated solution is diluted with water to 3L, petroleum ether (3L × 3 time), ethyl acetate (3L × 3 time) and water saturated n-butyl alcohol (3L × 3 time) is used to extract successively, concentrating under reduced pressure, obtains petroleum ether extract, acetic acid ethyl ester extract and n-butyl alcohol extract 212g respectively; (c) n-butyl alcohol extract 1.5L water dissolution, medical absorbent cotton filters, with AB-8 macroporous resin (2kg, column volume 1.5L) deposition activity composition, first use 8% alcohol flushing, 12 column volumes (18L) to remove large polar component, then use 70% ethanol elution, 10 column volumes (15L), collect 70% eluent, concentrating under reduced pressure, obtains Lysimachia trientaloides Hemsl. extract and is about 120g.
Embodiment 3: extract preparation (Lysimachia trientaloides Hemsl. 90 parts, 10 parts, Radix Glycyrrhizae)
Preparation method: by the Radix Glycyrrhizae dry rhizome co-grinding of the Lysimachia trientaloides Hemsl. of 9kg drying and 1kg, with 60% alcoholic solution circumfluence distillation (25L × 3 time), merge extractive liquid, is concentrated into and obtains ethanol extraction concentrated solution (2L) without alcohol taste; Gained ethanol extraction concentrated solution is diluted with water to 3L, petroleum ether (3L × 3 time), ethyl acetate (3L × 3 time) and water saturated n-butyl alcohol (3L × 3 time) is used to extract successively, concentrating under reduced pressure, obtains petroleum ether extract, acetic acid ethyl ester extract and n-butyl alcohol extract 212g respectively; (c) n-butyl alcohol extract 1.5L water dissolution, medical absorbent cotton filters, with AB-8 macroporous resin (2kg, column volume 1.5L) deposition activity composition, first use 8% alcohol flushing, 12 column volumes (18L) to remove large polar component, then use 70% ethanol elution, 10 column volumes (15L), collect 70% eluent, concentrating under reduced pressure, obtains Lysimachia trientaloides Hemsl. extract and is about 120g.
Embodiment 4: extract preparation (Lysimachia trientaloides Hemsl. 75 parts, 25 parts, Radix Glycyrrhizae)
Preparation method: by the Radix Glycyrrhizae dry rhizome co-grinding of the Lysimachia trientaloides Hemsl. of 7.5kg drying and 2.5kg, with 60% alcoholic solution circumfluence distillation (25L × 3 time), merge extractive liquid, is concentrated into and obtains ethanol extraction concentrated solution (2L) without alcohol taste; Gained ethanol extraction concentrated solution is diluted with water to 3L, petroleum ether (3L × 3 time), ethyl acetate (3L × 3 time) and water saturated n-butyl alcohol (3L × 3 time) is used to extract successively, concentrating under reduced pressure, obtains petroleum ether extract, acetic acid ethyl ester extract and n-butyl alcohol extract 212g respectively; (c) n-butyl alcohol extract 1.5L water dissolution, medical absorbent cotton filters, with AB-8 macroporous resin (2kg, column volume 1.5L) deposition activity composition, first use 8% alcohol flushing, 12 column volumes (18L) to remove large polar component, then use 70% ethanol elution, 10 column volumes (15L), collect 70% eluent, concentrating under reduced pressure, obtains Lysimachia trientaloides Hemsl. extract and is about 120g.
Embodiment 5: extract preparation (Lysimachia trientaloides Hemsl. 95 parts, 5 parts, Radix Glycyrrhizae)
Preparation method: by the Radix Glycyrrhizae dry rhizome co-grinding of the Lysimachia trientaloides Hemsl. of 9.5kg drying and 0.5kg, with 60% alcoholic solution circumfluence distillation (25L × 3 time), merge extractive liquid, is concentrated into and obtains ethanol extraction concentrated solution (2L) without alcohol taste; Gained ethanol extraction concentrated solution is diluted with water to 3L, petroleum ether (3L × 3 time), ethyl acetate (3L × 3 time) and water saturated n-butyl alcohol (3L × 3 time) is used to extract successively, concentrating under reduced pressure, obtains petroleum ether extract, acetic acid ethyl ester extract and n-butyl alcohol extract 212g respectively; (c) n-butyl alcohol extract 1.5L water dissolution, medical absorbent cotton filters, with AB-8 macroporous resin (2kg, column volume 1.5L) deposition activity composition, first use 8% alcohol flushing, 12 column volumes (18L) to remove large polar component, then use 70% ethanol elution, 10 column volumes (15L), collect 70% eluent, concentrating under reduced pressure, obtains Lysimachia trientaloides Hemsl. extract and is about 120g.
Embodiment 6: liquid-phase chromatographic analysis
Need testing solution is prepared: in the brown volumetric flask of extract 5mg to 50mL that Example 1 method is obtained, add 30mL10% acetonitrile solution ultrasonic dissolution, after being cooled to room temperature, continue to add 10% acetonitrile solution standardize solution.
Analytical method:
High performance liquid chromatograph: Agilent1260, binary pump;
Chromatographic column: AgilentZorbaxSB-C18 post (4.6mm × 250mm, 5 μm);
Mobile phase: A is acetonitrile, and B is 0.4% phosphoric acid solution;
Gradient elution program: 0 ~ 5min, A10% → 15%; 5 ~ 15min, A15% → 50%; 15 ~ 23min, A50% → 80%; 23 ~ 25min, A80% → 10%; 25 ~ 30min, A10%
Flow rate of mobile phase: 1.0mLmin
-1;
Determined wavelength: 280nm;
Column temperature: 30 DEG C;
Sample size: 10 μ L.
Analyze with the Lysimachia trientaloides Hemsl. extract of 10 batches of preparation, carry out chromatographic peak coupling, 1 ~ No. 7 peak all occurs in 10 batch sample chromatograms as a result, and all reaches baseline separation with surrounding chromatographic peak.Therefore demarcate 7 peaks for total chromatographic peak, set up the HPLC quality control collection of illustrative plates of this extract accordingly, the results are shown in Figure 1.
Embodiment 7: extract pharmacological testing
One, materials and methods
1.1 medicines and reagent: Lysimachia trientaloides Hemsl. extract 1. ~ 5. prepare according to embodiment 1 ~ 5 respectively, be made into experimental concentration with distilled water, be placed in 4 DEG C for subsequent use; SOD test kit builds up institute of biological products by Nanjing and provides; D-galactose is provided by Shanghai reagent two factory.
1.2 laboratory animals: Kunming mouse, body weight (20 ± 2) g, provided by Anhui Province's medical test.
1.3 experimental techniques: mice 70, male and female half and half, body weight (20 ± 2) g, is divided into 7 groups at random by mice, often organize 10, i.e. Normal group, D-gal Aging model group, Lysimachia trientaloides Hemsl. extract 1. ~ 5. group.Except Normal group, other six treated animals nape subcutaneous injections equal every day 5%D-galactose 0.5mL, normal group mice is nape subcutaneous injection normal saline 0.5mL then.In the 10d of injection of d-galactose, Lysimachia trientaloides Hemsl. extract 1. ~ 5. treated animal respectively gavage give Lysimachia trientaloides Hemsl. extract 1. ~ 5. 200mgkg
-1, Normal group mice and aging model treated animal then every day gavage equal-volume normal saline.Continuous use 30d.In last day gavage and injection of d-galactose 2h after, eye socket gets blood, anticoagulant heparin (4 DEG C of preservations) is for the mensuration of lipid peroxide in serum (LPO) content, then sacrificed by decapitation animal, takes out cerebral tissue and makes the assay of homogenate for catalase (CAT), superoxide dismutase (SOD), peroxidase (POD).
Two, result
2.1 Lysimachia trientaloides Hemsl. extracts are on the impact-ultraviolet spectrophotometry of CAT activity in brain aging mice serum
Table 1 shows, and under the effect of D-galactose, the CAT in model group animal brain is active significantly to decline, and compared with Normal group, difference is very remarkable.And gavage Lysimachia trientaloides Hemsl. extract group 1. ~ mouse blood 3. in CAT is active obviously rises (P<0.05), higher than model group; But fill with feed Lysimachia trientaloides Hemsl. extract group 4. ~ mouse blood 5. in CAT active in significantly improving, illustrate Lysimachia trientaloides Hemsl. extract 1. ~ 3. may have protective effect to CAT activity.
Note: compare * P<0.05 with model group, * * P<0.01.
Table 1 Lysimachia trientaloides Hemsl. extract is on the impact (X ± SD) of CAT activity in mice serum
| Group | Dosage/(mg/kg) | Protein content/mgmL -1 | CAT(k/gHb) |
| Normal group | - | 0.750 | 80.19±23.77 |
| Model group | - | 0.717 | 73.14±21.35 |
| Extract 1. | 200 | 0.701 | 90.83±8.16* |
| Extract 2. | 200 | 0.697 | 88.79±8.27* |
| Extract 3. | 200 | 0.700 | 89.75±8.13* |
| Extract 4. | 200 | 0.688 | 75.20±9.36 |
| Extract 5. | 200 | 0.691 | 76.43±8.91 |
2.2 Lysimachia trientaloides Hemsl. extracts are on the impact-tissue homogenate MDA colorimetry of LPO in brain aging Mice brain tissues
Table 2 shows, continuous subcutaneous injection 5% galactose aqueous solution, LPO content in Mice brain tissues is apparently higher than Normal group, illustrate that D-galactose can make cell membrane generation lipid peroxidation, and Lysimachia trientaloides Hemsl. extract 1. ~ the LPO content in Mice brain tissues 3. can be made to decline, with model group comparing difference obvious (P<0.05), point out it to have the effect of anti-lipid peroxidation, Lysimachia trientaloides Hemsl. extract 4. ~ 5. then the LPO content in Mice brain tissues is had no significant effect.
Note: compare * P<0.05 with model group.
Table 2 Lysimachia trientaloides Hemsl. extract is on the impact (X ± SD) of LPO in Mice brain tissues
| Group | Dosage/(mg/kg) | Number of animals (only) | MDA(nmoL/mgprot) |
| Normal group | - | 10 | 1.073±0.337 |
| Model group | - | 10 | 1.131±0.175 |
| Extract 1. | 200 | 10 | 1.032±0.124* |
| Extract 2. | 200 | 10 | 1.037±0.128* |
| Extract 3. | 200 | 10 | 1.035±0.120* |
| Extract 4. | 200 | 10 | 1.127±0.133 |
| Extract 5. | 200 | 10 | 1.125±0.125 |
2.3 Lysimachia trientaloides Hemsl. extracts are on the impact-photo-reduction NBT method of SOD activity in brain aging Mice brain tissues
Table 3 shows, fill with feed Lysimachia trientaloides Hemsl. extract 1. ~ Mice brain tissues 3. in significantly improve (P<0.01) SOD active comparison with model group; And fill with feed Lysimachia trientaloides Hemsl. extract 4. ~ Mice brain tissues 5. in SOD active in significant change.Prompting Lysimachia trientaloides Hemsl. extract 1. ~ 3. have obvious potentiation to the SOD activity in mouse aging cerebral tissue.
Table 3 Lysimachia trientaloides Hemsl. extract is to SOD activity influence (X ± SD) in Mice brain tissues
| Group | Dosage/(mg/kg) | Number of animals (only) | SOD vigor (μ/mgprot) |
| Normal group | - | 10 | 5.393±1.444 |
| Model group | - | 10 | 3.504±1.473 |
| Extract 1. | 200 | 10 | 6.252±1.366** |
| Extract 2. | 200 | 10 | 6.247±1.351** |
| Extract 3. | 200 | 10 | 6.244±1.372** |
| Extract 4. | 200 | 10 | 3.741±1.397 |
| Extract 5. | 200 | 10 | 3.726±1.401 |
Above-mentioned experimental result shows, Lysimachia trientaloides Hemsl. extract has the old effect of certain anti senile.In the present invention, the content of Radix Glycyrrhizae acts on most important to the anti senile of Lysimachia trientaloides Hemsl. extract always.
Embodiment 8: the preparation of tablet
Obtain extract by embodiment 1 method, add excipient, pelletizing press sheet in itself and excipient weight than the ratio for 1:10.
Embodiment 9: the preparation of oral liquid
By embodiment 1 method first obtained extract, oral liquid method for making makes oral liquid routinely.
Embodiment 10: the preparation of capsule or granule
By embodiment 1 method first obtained extract, add excipient in itself and excipient weight than the ratio for 1:9, make capsule or granule.
Embodiment 11: the preparation of injection
Obtain extract by embodiment 1 method, inject with water, fine straining, injection is made in embedding sterilizing.
Embodiment 12: the preparation of aseptic powder injection
By embodiment 1 method first obtained extract, be dissolved in sterile water for injection, stirring makes molten, filters with aseptic suction funnel, more aseptic fine straining, and be sub-packed in ampoule, after frozen drying, aseptic sealing by fusing obtains injectable powder.
Claims (6)
1. a Lysimachia trientaloides Hemsl. extract, it is characterized in that described extract is prepared by following methods: (a) by weight, every 100 parts of medical materials comprise dry Lysimachia trientaloides Hemsl. 80 ~ 90 parts and 10 ~ 20 parts, Radix Glycyrrhizae, co-grinding, with 60% alcoholic solution circumfluence distillation, merge extractive liquid, is concentrated into and obtains ethanol extraction concentrated solution without alcohol taste; B (), by step (a) gained ethanol extraction concentrated solution dilute with water, is used petroleum ether, ethyl acetate and water saturated n-butanol extraction successively, concentrating under reduced pressure, is obtained petroleum ether extract, acetic acid ethyl ester extract and n-butyl alcohol extract respectively; C () n-butyl alcohol extract water dissolution, filters, uses macroporous resin enrichment active component, first remove large polar component with 8% alcohol flushing, 12 column volumes, then use 70% ethanol elution, 10 column volumes, collect 70% eluent, concentrating under reduced pressure and get final product.
2. extract according to claim 1, is characterized in that: macroporous resin described in step (c) is that AB-8 type is large
Hole resin.
3. extract according to claim 1, is characterized in that: the liquid phase analysis method of described extract is:
Chromatographic column: AgilentZorbaxSB-C18 post (4.6mm × 250mm, 5 μm);
Mobile phase: A is acetonitrile, and B is 0.4% phosphoric acid solution;
Gradient elution program: 0 ~ 5min, A10% → 15%; 5 ~ 15min, A15% → 50%; 15 ~ 23min, A50% → 80%;
23~25min，A80%→10%；25~30min，A10%
Flow rate of mobile phase: 1.0mLmin-1;
Determined wavelength: 280nm;
Column temperature: 30 DEG C;
Sample size: 10 μ L.
4. pharmaceutical preparation, is characterized in that: containing the treatment extract according to claim 1 of effective dose and pharmaceutically acceptable
Carrier.
5. the application of extract according to claim 1 in the medicine that preparation treatment anti senile is old.
6. the application of pharmaceutical preparation according to claim 4 in the medicine that preparation treatment anti senile is old.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510733252.XA CN105232619A (en) | 2015-11-02 | 2015-11-02 | Lysimachia trientaloides hemsl. extract as well as preparation method and medical application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510733252.XA CN105232619A (en) | 2015-11-02 | 2015-11-02 | Lysimachia trientaloides hemsl. extract as well as preparation method and medical application thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN105232619A true CN105232619A (en) | 2016-01-13 |
Family
ID=55030618
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510733252.XA Withdrawn CN105232619A (en) | 2015-11-02 | 2015-11-02 | Lysimachia trientaloides hemsl. extract as well as preparation method and medical application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105232619A (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105815783A (en) * | 2016-03-22 | 2016-08-03 | 张利文 | Snow lotus herb extract-containing food additive with sleep improving effect |
| CN108938688A (en) * | 2018-09-27 | 2018-12-07 | 贵阳中医学院 | Application of the starflowerlike loosestrife root or herb in the drug for preparing anti-norepinephrine induction disease |
| CN108938689A (en) * | 2018-09-27 | 2018-12-07 | 贵阳中医学院 | Application of the starflowerlike loosestrife root or herb in preparation enhancing hematological system immunity drug |
| CN109106734A (en) * | 2018-09-27 | 2019-01-01 | 贵阳中医学院 | Application of the starflowerlike loosestrife root or herb in the drug of preparation prevention and treatment er stress induction disease |
-
2015
- 2015-11-02 CN CN201510733252.XA patent/CN105232619A/en not_active Withdrawn
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105815783A (en) * | 2016-03-22 | 2016-08-03 | 张利文 | Snow lotus herb extract-containing food additive with sleep improving effect |
| CN108938688A (en) * | 2018-09-27 | 2018-12-07 | 贵阳中医学院 | Application of the starflowerlike loosestrife root or herb in the drug for preparing anti-norepinephrine induction disease |
| CN108938689A (en) * | 2018-09-27 | 2018-12-07 | 贵阳中医学院 | Application of the starflowerlike loosestrife root or herb in preparation enhancing hematological system immunity drug |
| CN109106734A (en) * | 2018-09-27 | 2019-01-01 | 贵阳中医学院 | Application of the starflowerlike loosestrife root or herb in the drug of preparation prevention and treatment er stress induction disease |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP2937094B1 (en) | Pharmaceutical composition for treating headache, and preparation method thereof | |
| CN102370761B (en) | Traditional Chinese medicine compound recipe used for preventing or resisting allergy, preparation method thereof, and application thereof | |
| CN105232619A (en) | Lysimachia trientaloides hemsl. extract as well as preparation method and medical application thereof | |
| CN105125620A (en) | Caesalpinia decapetala extract and preparing method and medical application thereof | |
| CN1775276A (en) | Fushu Preparation and new preparing method | |
| CN105079308A (en) | Common rockvine herb extract as well as preparation method and pharmaceutical application of extract | |
| CN105147907A (en) | Dasheen flower extract, as well as preparation method and medicinal application thereof | |
| CN105362975A (en) | Traditional Chinese medicine granule for treating postpartum lochiorrhea and lesser-abdominal pain and preparation method thereof | |
| CN105055544A (en) | Plant extract capable of preventing brain aging | |
| CN104958333A (en) | Panax japonicus extract and medical application thereof | |
| CN105233022A (en) | Remote lemongrass herb extract and preparation method and medical appliance thereof | |
| CN105168373A (en) | Blood fat-reducing glossy privet fruit extract and preparation method thereof | |
| CN105106276A (en) | Tradescantia extract as well as preparation method and medical application of tradescantia extract | |
| CN105106558A (en) | Brain aging resistance hosta ventricosa extract and preparation method | |
| CN105232627A (en) | Solidago extract and preparation method and medical application thereof | |
| CN101549008B (en) | Application of high-pressure continous extracted cassia seed extract in preparing hypolipemic medicine | |
| CN105193887A (en) | Acanthopanax senticosus extract and antioxidation application thereof | |
| CN105079293A (en) | Cirald daphne bark extract, as well as preparation method and medical application thereof | |
| CN101940318B (en) | Soft capsule with functions of relieving cough, anti-inflammation and reducing blood lipid and preparation method thereof | |
| CN105327127A (en) | Smallflower epipactis flower extract resisting brain aging and preparing method of smallflower epipactis flower extract | |
| CN107088208A (en) | A kind of Folium Callicarpae Formosanae extract, the preparation method and medical usage of the extract | |
| CN105125652A (en) | Tsinling larkspur root extract and preparing method and medical application thereof | |
| CN100453073C (en) | Compound radical lobelia dripping pill and its preparing method | |
| CN108904566A (en) | The preparation method of flavones ingredient in a kind of FLOS CHRYSANTHEMI ALBA from Haizhou of China | |
| CN105079144A (en) | Cimicifugae foetidae extract having effects of diminishing inflammation and relieving pain and preparation method of cimicifugae foetidae extract |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| CB02 | Change of applicant information |
Address after: 311802, Shaoxing City, Zhejiang province Zhuji Ruan Town soup Village Applicant after: Zhuang Li Address before: 325016 Zhejiang Province, Wenzhou city Ouhai District streets Quxi Road No. 26 reform Applicant before: Zhuang Li |
|
| COR | Change of bibliographic data | ||
| WW01 | Invention patent application withdrawn after publication | ||
| WW01 | Invention patent application withdrawn after publication |
Application publication date: 20160113 |